Clinical Trial

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereby informing subsequent clinical dosing regimens. To assess the objective response rate (ORR) of the combination regimen in this patient population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-22.
Trial Details
NCT Number NCT07320963
Lead Sponsor Sun Yat-sen University
Collaborators: Fujian Cancer Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Nasopharyngeal Carcinoma
Enrollment 52 participants
Start Date 2026-03-31
Primary Completion 2027-03-28 (estimated)
Study Completion 2028-03-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-20